Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aspen Aerogels Inc (ASPN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Aspen Aerogels IncTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Aspen Aerogels Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Aspen Aerogels Inc trades at $6.16 (market cap $509.55M), while Vertex Pharmaceuticals Incorporated trades at $525.76 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 263.5× Aspen Aerogels Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Aspen Aerogels Inc nearer its low. Which is the better fit depends on your goals.

ASPNVRTX
Market Cap
$509.55M$134.25B
Sector
TechnologyHealth
52-Week High
$8.82$529.65
52-Week Low
$2.57$376.62
Enterprise Value
$482.96M$128.37B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aspen Aerogels Inc

ASPN trades at $6.14, down 2.38% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $389.55 million in 2025, though Q2 2026 revenue beat estimates and Q3 guidance suggests recovery. Analyst consensus is strongly bullish with 82.61% buy ratings.

Outlook hinges on execution of revenue growth and margin improvement, particularly in thermal barrier segments. Risks include persistent negative profitability, high cash burn, and competitive pressures in EV materials. The stock offers speculative upside if operational targets are met.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $526.33, up 0.46% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with 2025 revenue of $12.0B and net income of $3.95B, though recent Q2 2026 earnings slightly missed estimates. Analyst sentiment remains positive with an 83.9% buy rating and a $534.25 consensus price target, while news highlights raised 2026 sales guidance driven by cystic fibrosis drug strength and newer product launches.

The outlook for VRTX is favorable given robust revenue growth, high profitability margins, and raised full-year guidance. Key opportunities include diversification beyond cystic fibrosis with newer products, but risks involve earnings volatility, competitive pressures, and execution on pipeline developments. The stock's valuation at a P/E of 30.85 requires sustained growth to justify further upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aspen Aerogels Inc

Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.

Read more on ASPN

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX